Osteoporosis Musculoskeletal Diseases Osteoporosis without pathological fracture
Conditions
Interventions
The Calci-Chew D3 chewable tablets (Nycomed, Denmark) contained 1250 mg of calcium carbonate (equivalent to 500 mg elemental calcium) and 400 IU of cholecalciferol (equivalent to 10 µg vitamin D3). Th
Sponsors
Nycomed (Denmark)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients with osteoporosis who required calcium and vitamin D supplementation as part of their anti-osteoporotic therapy 2. Age range: greater than 18 years, gender: women and men
Exclusion criteria
Exclusion criteria: 1. Use of the trial medications during the past six months 2. Any condition for which the trial medications are contra-indicated, such as hypercalcaemia, hypercalciuria, Zollinger-Ellison syndrome, and nephrolithiasis 3. Use of drugs known to interact with the trial medications (e.g., digoxin, tetracycline, fluoroquinolones, bisphosphonates, iron, sodium fluoride, diuretics, phenytoin, barbiturates, corticosteroids, levothyroxine, ion exchange resins, laxatives) 4. Planned surgery during the four-week study period 5. Pregnant, possibly pregnant, or breastfeeding women
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To assess any preference between Calci-Chew D3 and Cad, measured at visit 3 (day 28). | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. To compare acceptability of the formulations using an 11-point rating scale, measured at visit 2 (day 14) and visit 3 (day 28) 2. To record tolerability and adverse events, measured at visit 2 (day 14) and visit 3 (day 28) | — |
Countries
Netherlands
Outcome results
None listed